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Postoperative anal pain is one of the main adverse effects of surgical treatment of benign
anorectal diseases and remains a distressing problem, for both patients and physicians.
Postoperative pain control is important yet it remains an unresolved issue which causes

Keywords
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 postoperative

patient dissatisfaction and negatively impact quality of life. This review article studied
the analgesic effect of topical and oral metronidazole after benign anorectal surgery.
Seven studies used oral metronidazole and six used topical metronidazole. The studies
showed that post operative pain score of patients who had metronidazole by either route
was significantly less than those in comparison groups. The pain score decreased at all
the time points for both oral and topical metronidazole. Overall, the analgesic effect of
oral metronidazole was inconsistent among published studies. When topical and oral
metronidazole were compared the post operative pain score and analgesic consumption
were lower in topical metronidazole than the oral group
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INTRODUCTION

Signal one

Immunotherapy is now a pillar of cancer

(Antigen Processing & Presentation)

therapy. In which, it mediates its effect through

T cells are developed in the thymus gland to be

activation of the host immune system to fight

specific for antigen. CD4+ helper T-cells and CD8+

malignant cells, different from chemotherapy,

cytotoxic T-cells recognize their antigen which is

which exert its effect by cytotoxic properties.

attached to major histocompatibility complex

Many immunotherapies have been developed such

(MHC), found on APC's surface. This triggers and

as vaccines and antibody therapies. We are going

aids the initial activation of the T cells(3).

to focus on Chimeric Antigen Receptor (CAR) T-

Signal two

cell

(Co-stimulation)

therapy and it is role in acute lymphoblastic

After T cell receptor (TCR) binds to antigen-

leukemia treatment (1).

loaded MHC, both CD4+ and CD8+ T cells will be

CAR T-cell therapy is a recent modality which

activated by 2ry signals and respond potently to

uses the own T cells of the patient, CAR which

the pathogen. For CD4+ T cells, CD28 will provide

represents the genetically engineered and modified

the 1st signal. (3). While, CD8+ T cells activation

fraction of the T cells, includes protein that permit

needs signals from 4-IBB(CD137) and CD 70

T cells to attack the malignant cells. CAR T can

(3)Fig 1.

provide long term control of the disease and
potential protection against relapse (2).
T-cell activation

Figure 1. Schematic of early T cell activation (3).
Recently

approved CAR T-cells use CAR

Signal three

constructs consisting of a single‐chain variable

After the second signal, T cells subtype will be

fragment antigen‐recognition domain, a

identified based on specific antigen signal and
cytokines (3).

co-stimulatory domain (CD28 and/or 4‐1BB) (4).

Chimeric antigen receptor design
CAR T cells are manufactured by introducing a
genetically engineered

CD3‐derived T‐cell activation domain and a

Fig 2.

CAR fusion protein by

means of a retrovirus into autologous T-cells.
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First-generation CARs failed to make antitumor

(known as TRUCK T cell) have the ability to

effects. It consists of a CD3 domain and a tumor

liberate

antigen-binding domain (5).

this transgenic protein to regulate T-cell response.

Second-generation

CARs

provide

a

better

The advantage of 4th generation CAR -T is the

cytokine production and proliferation

ability to also reactivate innate immune cells to

Third-generation CARs have a better effect than

attack the antigen

nd

2 generation due to two co-stimulatory domains

-negative cells & self-withdrawal mechanism,

(CD28 or CD137 and/or others as ICOS, CD27, or

once antitumor effect is achieved (5).because of

CD134) addition (5).

co-stimulatory domain (CD28 or CD137) addition
(5).

The fourth generation CAR is engineered with a
cytokine (IL-12). The T cells are directed for
antigen‐unrestricted

cytokine‐initiated

killing

Figure 2. Schematic representation of four types of CARs (6)
activated protein kinase (MAPK) and Jun Nterminal kinase (JNK)(9).

Chimeric Antigen Receptor mechanism
Choosing an ideal target is essential

in the

Downstream

to

this

activation

of

NF-kB,

design of powerful cellular immunotherapies and

phosphoinositide 3 kinase (PI3K) and protein

to minimize the toxicities. CD19 antigen remains

kinase B (PKB), 4-IBB then upregulates anti-

the most widely used as it

apoptotic factors such as Bcl-2, Bcl-xl, and Bfl-

is upregulated on

malignant B cell (7, 8) Fig 3.

1(9).

Tisagenlecleucel activation is achieved through 41BB (CD137), which is essential to activate
nuclear factor-kB (NF-kB) via p38 mitogen-
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Figure 3. Anatomy for T cell engineers: T cell receptor and CAR binds to surface molecules on tumor cells (10)

followed
It

also

acts

endogenous
cell

through

TCR

signaling

proliferation,

cell-cycle

leading

via

kinase

with
to

T-

for

manufacturing

During

extracellular

receive

(ERK)

and

the

this

time,

chemotherapy

CAR T-Cell therapy phases

therapy, Table 1(12).

cell

therapy

evaluation

eligibility

will

for

CAR

take

immune

that

the

patient’s

in

the

After

laboratory.

the

patient

lymphodepleting

PI3K, prevention of clonal deletion(11).
Initially

leukapheresis.

that, the collected T cells are transferred

secretion,

cytokine

progression

signal-regulated

interaction

by

system

will
to

will

conditioning
aid

preparing

support

this

T-

place,

Table 1.Six Phases Of CAR T-Cell Therapy(12)
Phase
Consultation
workup

Definition
Evaluation of patients for CAR
T cell therapy eligibility.

Key features
This includes confirmation of patient
eligibility to ensure readiness for therapy.

Leukapheresis

It consists of WBCs collection
from the patient through
apheresis catheter.

Laboratory criteria, such as complete blood
count, is considered.

Bridging

After WBCs collection from the
patient, the T cells are separated
and sent to the manufacturing
facility where they undergo
genetic modification to express
the specific CAR.

Manufacturing
sometimes
may
be
unsuccessful because of the product being
out of FDA specification.
Options
may
include
a
second
leukapheresis.

Patient education considerations
It includes structured history, physical
examination,
and
laboratory
investigations.
Education for patient & caregiver should
focus on the leukapheresis procedure and
side effects, such as fatigue, cytopenias,
or hypocalcemia.
Manufacturing takes at least 2 weeks.
Chemothrerapy is used during this phase
to prevent relapse, debulk the tumor, and
maintain performance status without
undue toxicity.

Lymphodepleting
chemotherapy

This phase includes re-staging
the patient and the delivery of
lymphodepleting conditioning
regimen before CAR T-cell
infusion.
This phase includes CAR T
cells infusion and observation
during and post- infusion for
toxicities and response.
This phase includes re-staging,
which is done 30–90 days postinfusion.

Regimen
includes
fludarabine
and
Cyclophosphamide given over 3 days.

Conditioning regimen may be received in
the inpatient or outpatient setting.

The specifics on infusion of CAR T-cell
products are well defined in package inserts
per FDA guidelines.

When the CAR T cells begin attacking
cancer cells, they proliferate and can
cause manifestations of CRS and
neurologic toxicity.
Following treatment, patients’ needs
accurate
follow-up
to
manage
complications .

Infusion
monitoring

and

and

Long-term followup

https://mmj.mans.edu.eg/home/vol51/iss1/1
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CHIMERIC ANTIGEN RECEPTOR CELLS

effector cell-associated neurotoxicity syndrome

TOXICITY

(ICANS).

While CAR T-cell therapy has shown impressive

aplasia, prolonged cytopenias and risk for

results, acute toxicities can be fatal such as

opportunistic

cytokine release syndrome (CRS) and neurological

recognized

Also delayed toxicities as B-cell

infections

are

being

clearly
(13)fig.4.

toxicity, immune

Figure 4.CAR T-Cell Toxicities Timeline (14).
CRS is an inflammatory syndrome caused by

Determinants of CAR T-cell toxicity include

numerous cytokines and inflammatory markers

patient-related factors as ALL, disease burden,

such as C-reactive protein, ferritin, interferon-ϒ,

baseline low platelet

interleukins,

count, and baseline elevated markers of endothelial

and

macrophage

inflammatory

protein-1(13).

activation, and therapy specific factors as high

ICANS can occur alongside with CRS or more

CAR doses and fludarabine based -conditioning

after CRS been settled down.

regimens (13).

It still unclear

why CAR T cells travel CNS in the absence of
disease.
activation

A report found that endothelial
and

blood

brain

barrier

GRADING OF CRS AND ICANS

(BBB)

The variations in toxicities grading among

disruption might contribute to CAR T‐cell

institutions exposed the importance to promote a

trafficking and CNS toxicity. Other studies

common grading system for CAR T–cell‐related

indicated a role for myeloid cell activation in the

toxicities. The American Society For Blood And

CNS. Lastly, studies in mice showed that blocking

Marrow Transplantation (ASBMT) published the

IL-1 with anakinra, neurologic toxicity & CRS

ASBMT Grading System for CRS(Table 2) and

were eliminated(15).Factors contributing to

ICANS (Table 3)(16).

CAR T-cell toxicity
Table 2. ASBMT CRS Consensus grading (16)
Parameter

Grade 1

Grade 2

Grade 3

Grade 4

Temp ≥ 38°C

Fever
Hypotension

-

Not
demanding
vasopressor

± vasopressin

Demanding vasopressors
vasopressin)

Hypoxia

-

Demanding low-flow
nasal
cannula or
blow-by

Demanding high-flow nasal
cannula, non-rebreather mask,
or Venturi mask

Demanding positive pressure

Published by Mansoura Medical Journal, 2023
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Table 3. ASBMT ICANS Consensus grading (16, 17)
Neurotoxicity Domain

Grade 1

Grade 2

Grade 3

Grade 4

7-9

3-6

0-2

0

Awakens only to tactile
stimulus

Patient is unarousable or
requires
vigorous
or
repetitive tactile stimuli to
arouse; stupor or coma
Life-threatening
prolonged
seizure (> 5 mins) or
repetitive clinical or electrical
seizures without return to
baseline in between
Deep focal motor weakness
such as hemiparesis or
paraparesis
Diffuse cerebral edema on
neuroimaging; decerebrate or
decorticate posturing; or
cranial nerve VI palsy; or
papilledema; or Cushing’s
triad

ICE score*
Depressed level of consciousness

Awakens
spontaneously

Awakens
to voice

Seizure

-

-

Motor findings

-

-

Elevated ICP/cerebral edema

-

-

Any clinical seizure that
rapidly resolves or nonconvulsive seizures on
EEG which resolves
with intervention
-

Focal
edema
neuroimaging

on

Indications of CAR in ALL patients

Limiting the presence of a negative CD19 clones

The FDA approved the use of Tisagenlecleucel for

might be defeated by manufacturing binary

ALL treatment. It was approved based on a study

targeted CARTs. New targets as CD22 has shown

involved 63 relapsed or refractory B - ALL

to be a new effective target in B-cell ALL (21).

patients (18).
Uses of CAR-T cells includes relapsed cases who

Conclusion

have

failed

many

previous

regimens,

as

CAR T cells have dramatically improved the

stem

cell

transplantation

or

immunotherapeutic treatment of cancer: Great

blinatumomab, patients with positive Philadelphia

results related to hematolgical cancers have been

chromosome disease, those with refractory ALL,

accomplished. Neurotoxicity and CRS remain the

cases with Down syndrome and in patients with

barrier for widely use of this therapy.

hematopoietic

extramedullary disease (19).
Data concerning use of CAR T cell therapy in

References

treatment of patients with CNS disease is limited.
However, CAR-T cells can cross the BBB
resulting in CNS

remissions

is

a

1.

critical

Abbott M, Ustoyev Y, editors. Cancer and
the immune system: The history and

observation (20).

background of immunotherapy. Seminars in

The future of CAR cell therapy for ALL

oncology nursing; 2019: Elsevier.

Full potential optimization still the main challenge

2.

Pagel JM, West HJJJo. Chimeric antigen

for this therapy. The Limitation of CD19 positive

receptor

relapses

2017;3(11):1595-.

could

be

achieved

by

a

good

(CAR)

T-cell

therapy.

understanding for the biology of persistence.

https://mmj.mans.edu.eg/home/vol51/iss1/1
DOI: 10.21608/mjmu.2021.103500.1048

6

khafagy et al.: Could CAR-T cell therapy be promising agent in acute lymphoblasti
CAR T-cell therapy for ALL

3.

Cavanagh Mary. T-cell activation 2018

and opportunities in translating innovative

[Available

treatment concepts. 2017;9(9):1183-97.

from:

https://www.immunology.org/public-

4.

5.

Li L, Boussiotis VAJSs. Selective effects of

and-processes/t-cell-activation.

PD-1 on Akt and Ras pathways regulate

Sermer D, Brentjens RJHo. CAR T‐cell

molecular components of the cell cycle and

therapy: Full speed ahead. 2019;37:95-100.

inhibit

Tahmasebi

2012;5(230):ra46-ra.

S,

Elahi

R,

Khosh

AJC,

Oncology

E,
T.

Beaupierre A, Lundberg R, Marrero L,

Management across settings: An ambulatory

therapy. 2020:1-17.

and community perspective for patients

Kalaitsidou M, Kueberuwa G, Schütt A,

undergoing CAR T-cell therapy in multiple

Gilham DEJI. CAR T-cell therapy: toxicity

care settings. 2019.
13.

M,

Wang

T,

Alencar

advances

Davila ML, Riviere I, Wang X, Bartido S,

mechanisms,

Park J, Curran K, et al. Efficacy and

management. 2019;34:45-55.
14.

MC.

Brudno JN, Kochenderfer JNJBr. Recent

2015;7(5):487-97.

in

CAR

T-cell

toxicity:

manifestations

and

Nastoupil LJ, Jain MD, Spiegel JY,

therapy in B cell acute lymphoblastic

Ghobadi A, Lin Y, Dahiya S, et al.

leukemia. 2014;6(224):224ra25-ra25.

Axicabtagene ciloleucel (Axi-cel) CD19

Norelli

M,

Casucci

M,

C,

chimeric antigen receptor (CAR) T-cell

Clinical

therapy for relapsed/refractory large B-cell

Bonini

AJBeBA-RoC.

pharmacology of CAR-T cells: Linking

lymphoma:

cellular

2018;132(Supplement 1):91-.

pharmacodynamics

to

pharmacokinetics and antitumor effects.

15.

real

Curran

Vairy S, Garcia JL, Teira P, Bittencourt

management

HJDd,

2016;3:16011.

development,

relapsed

and

therapy.

CAR-T

refractory

CTL019

therapy
B-cell

for
acute

16.

world

experience.

Bonifant CL, Jackson HJ, Brentjens RJ,

2016;1865(1):90-100.

(tisagenlecleucel):

KJJMT-O.
in

CAR

Toxicity
T-cell

and

therapy.

Lee DW, Santomasso BD, Locke FL,
Ghobadi A, Turtle CJ, Brudno JN, et al.
ASTCT consensus grading for cytokine

lymphoblastic leukemia. 2018;12:3885.
10.

proliferation.

new breakthrough in cancer CAR-T cell

Bondanza

9.

cell

Jain

toxicity management of 19-28z CAR T cell

8.

12.

T

Programmable and multi-targeted CARs: a

and the relevance of preclinical models.

7.

Patsoukis N, Brown J, Petkova V, Liu F,

information/bitesized-immunology/systems-

Esmaeilzadeh

6.

11.

M,

release syndrome and neurologic toxicity

Bondanza A, Buchholz CJJEmm. Clinical

associated with immune effector cells.

development of CAR T cells—challenges

2019;25(4):625-38.

Hartmann

J,

Schüßler‐Lenz

Published by Mansoura Medical Journal, 2023

7

Mansoura Medical Journal, Vol. 51 [2023], Iss. 1, Art. 1
Khafagy et al.,

17.

8

Neelapu SSJHo. Managing the toxicities of
car T‐cell therapy. 2019;37:48-52.

18.

Mullard AJNrDd. FDA approves first CAR
T therapy. 2017;16(10):669.

19.

Hucks G, Rheingold SRJBcj. The journey
to CAR T cell therapy: the pediatric and
young adult experience with relapsed or
refractory B-ALL. 2019;9(2):1-9.

20.

Santomasso BD, Park JH, Salloum D,
Riviere I, Flynn J, Mead E, et al. Clinical
and biological correlates of neurotoxicity
associated with CAR T-cell therapy in
patients with B-cell acute lymphoblastic
leukemia. 2018;8(8):958-71.

21.

Fry TJ, Shah NN, Orentas RJ, StetlerStevenson M, Yuan CM, Ramakrishna S,
et al. CD22-targeted CAR T cells induce
remission in B-ALL that is naive or resistant
to CD19-targeted CAR immunotherapy.
2018;24(1):20.

https://mmj.mans.edu.eg/home/vol51/iss1/1
DOI: 10.21608/mjmu.2021.103500.1048

8

